API | volociximab

volociximab Report issue

Biologics mAb Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Volociximab is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
volociximab

More Chemistry

Pharmacology

Mechanisms of Action:
- Integrin alpha-5 (Homo sapiens) ^UniProt
- Integrin beta-1 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

m200 | volociximab

Organizations (29)

Research & Development (29)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 2)

Hamartoma (Phase 1/Phase 2)

Lung Neoplasms (Phase 2)

Macular Degeneration (Phase 1)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial Organizations: 29

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue